Modeste Danielle, Stewart Christopher, Premanandhan Hajani, Awad Mahmoud Husseiny, Williams Gwyn Samuel
Ophthalmology, Singleton Hospital, Swansea Bay University Health Board, Swansea, Wales, UK.
Swansea Bay University, Medical School, Swansea, Wales, UK.
Clin Ophthalmol. 2024 Oct 7;18:2821-2829. doi: 10.2147/OPTH.S468458. eCollection 2024.
To evaluate the efficiency and safety of Faricimab on treatment-naive neovascular age related macular degeneration (nAMD) in a real world UK clinic.
This single centre, retrospective note review was conducted on treatment-naive patients with nAMD. The data collected included demographics, best corrected visual acuity (BCVA), central macular thickness (CMT), total retinal fluid (TRF), the presence of intraretinal fluid (IRF) and subretinal fluid (SRF).
A total of 66 eyes from 62 patients were analysed. The average age was 77 years (range 36-91) and 54% of patients were female. After the first dose of faricimab, the average BCVA improved by 0.05 LogMAR (+2.5 letters), the average CMT decreased by 65.9μm and 41% of patients were found to be inactive. The follow-up intervals after the third loading dose were divided into 2 subsets of 4 and 8 week extensions. The 4 week extension subset saw a smaller improvement in BCVA (+3 letters) than the 8 week extension (+6 letters) while both had an average decrease in CMT by 86.6 μm. The total retinal fluid decreased by 45% and 70.7%, leaving only 30% and 12.2% residual intraretinal fluid (IRF) and 30% and 24.4% residual subretinal fluid (SRF), respectively. Over a ten-month period, the average number of injections received was 6.6, including 3 initial loading doses. There was only one reported case of an adverse event out of 66 eyes (1/66, 1.5%).
Three loading doses of Faricimab appear efficacious and safe for the treatment of nAMD.
评估法西单抗在英国一家现实世界诊所中治疗初治新生血管性年龄相关性黄斑变性（nAMD）的有效性和安全性。
对nAMD初治患者进行了这项单中心回顾性病历审查。收集的数据包括人口统计学信息、最佳矫正视力（BCVA）、中心黄斑厚度（CMT）、视网膜总液量（TRF）、视网膜内液（IRF）和视网膜下液（SRF）的存在情况。
共分析了62例患者的66只眼。平均年龄为77岁（范围36 - 91岁），54%的患者为女性。首次注射法西单抗后，平均BCVA提高了0.05 LogMAR（相当于提高2.5行视力），平均CMT降低了65.9μm，41%的患者病情无进展。第三次负荷剂量后的随访间隔分为4周延长组和8周延长组两个亚组。4周延长组的BCVA改善程度（提高3行）小于8周延长组（提高6行），而两组的CMT平均下降均为86.6μm。视网膜总液量分别减少了45%和70.7%，视网膜内液残留率分别仅为30%和12.2%，视网膜下液残留率分别为30%和24.4%。在10个月的时间里，平均注射次数为6.6次，包括3次初始负荷剂量。66只眼中仅报告了1例不良事件（1/66，1.5%）。
法西单抗的三次负荷剂量治疗nAMD似乎有效且安全。
